These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2416 related items for PubMed ID: 27352986

  • 21. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
    Giunzioni I, Tavori H.
    Vasc Health Risk Manag; 2015; 11():493-501. PubMed ID: 26345307
    [Abstract] [Full Text] [Related]

  • 22. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
    Kolovou V, Katsiki N, Makrygiannis S, Mavrogieni S, Karampetsou N, Manolis A, Melidonis A, Mikhailidis DP, Kolovou GD.
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 26. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V.
    Circulation; 2016 Nov 29; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C, Banach M, Corsini A, Sirtori CR, Ferri N, Ruscica M.
    Eur J Prev Cardiol; 2019 Jun 29; 26(9):930-949. PubMed ID: 30776916
    [Abstract] [Full Text] [Related]

  • 29. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M, Skripuletz T, Napp LC, Berliner D, Akin I, Haghikia A, Akin E, Bauersachs J.
    Cardiovasc Hematol Agents Med Chem; 2017 Jun 29; 14(2):94-100. PubMed ID: 27470008
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Anti-PCSK9 Antibodies: A New Era in the Treatment of Dyslipidemia.
    Schmitz J, Gouni-Berthold I.
    Curr Pharm Des; 2017 Jun 29; 23(10):1484-1494. PubMed ID: 28137217
    [Abstract] [Full Text] [Related]

  • 34. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.
    Atherosclerosis; 2019 Sep 29; 288():85-93. PubMed ID: 31349086
    [Abstract] [Full Text] [Related]

  • 35. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
    Roth EM, Davidson MH.
    Rev Cardiovasc Med; 2018 Sep 29; 19(S1):S31-S46. PubMed ID: 30207556
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K, Reinecke H.
    Vasa; 2018 Apr 29; 47(3):165-176. PubMed ID: 29412075
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 121.